MedTrace Logo

Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed

NCT00259844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-07-18

No results posted yet for this study

Summary

This study will test the safety and efficacy of TroVax in patients undergoing surgical resection of colorectal cancer with liver metastases.

TroVax potentially works by encouraging the immune system to react against the 5T4 protein on the surface of bowel cancer cells. The immune system is then able to recognise 5T4 and kill cells that carry it. The hope is that if tumour cells started to grow again after the main tumour has been surgically removed, the immune system would be able to find and destroy them.

Conditions

  • Colorectal Neoplasms

Interventions

BIOLOGICAL

TroVax

Sponsors & Collaborators

Principal Investigators

  • Robert Hawkins, MD, Prof · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259844 on ClinicalTrials.gov